63-PUB: Diabetes Control and Complications in South India—Three-Year Results of LANDMARC Trial

Glycemic control, therapy trends, and diabetes complications were evaluated in LANDMARC — a prospective observational 3-year (y) study (CTRI/2017/05/008452) of participants with T2D on ≥2 antihyperglycemic medications. This sub-analysis of 135 sites in South India (Bangalore, Chennai, Coimbatore, Hyderabad, Kerala, and Vijayawada) included 2354 participants (mean SD baseline BL age: 51.4 9.2 y, T2D duration: 8.4 5.5 y and A1C: 8.1% 1.6). At BL, most were insulin-naïve (n=1665; 70.8%), mainly on OADs (n=1638; 69.6%). At 3 y, 1149 (57.8%) participants were on OADs only, while 806 (40.5%) were on insulin + OADs. Biguanides was the most prescribed drug class (BL: 2184/2353 92.8% and 3 y: 1853/1988 93.2%). Basal insulin usage increased from BL (n=335; 14.2%) to 3 y (n=465; 23.4%). A decrease in mean (SD) A1C (-0.6 1.7 %), FPG (-18.0 60.3 mg/dL), and PPG (-30.3 81.5 mg/dL); and an increase in those with A1C7% (BL: 414 24.5%; 3 y: 440 30.1%), was noted. MI and neuropathy were the most common macro and microvascular complications, respectively (Table). The rate of microvascular complications (n, %) was highest in South India (519, 22.1%) vs. West (252, 18.8%), North (243, 14.4%) and East (107, 12.7%) at 3 y. Hypertension and dyslipidemia were the most common CV risk factors. There is need to further evaluate diabetes management strategies employed in South India to achieve optimal glycemic control. Disclosure H. Thacker: Other Relationship; Merck Sharp Sanofi. B. Ramanathan: None. A.K. Asirvatham: None. M. Shunmugavelu: None. M.D. Mruthyunjaya: None. C. Selvan: None. V. Sundaram: None. E. Philip: Other Relationship; Sanofi, Novo Nordisk, Eris Lifesciences Ltd. Research Support; Sun Pharmaceutical Industries Ltd. S.K. Menon: Employee; Sanofi. A. Gadekar: None. D. Chodankar: Employee; Sanofi. Funding Sanofi